Final 5-year analysis of a phase 3 trial in untreated HLA-A*02:01-positive metastatic uveal melanoma: tebentafusp vs investigator's choice gave median OS 21.6 vs 16.9 months (HR 0.67, 95% CI 0.54-0.85); 5-year OS 16% vs 8%.
RCT
Piperno-Neumann et al. Five-year survival with tebentafusp in metastatic uveal melanoma